Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
64.00    1.00 (1.59%)
Bid:
60.00
Ask:
63.00
Spread: 3.00 (5.00%)
Market Cap: £52.12m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Update

27 Mar 2008 07:02

Flomerics Group PLC27 March 2008 Flomerics Group PLC ("Flomerics" or "the Company") Update Flomerics, the global supplier of specialist simulation software for electronicsand fluid flow simulation, is today providing an update on its operational plansand outlook for 2008 and beyond in the light of the recent changes inshareholdings in the Company. Flomerics' strategy remains to be a leading provider of software simulationsolutions to the worldwide engineering design market. Flomerics' softwaresolutions are targeted at the world electronic thermal management and fluid flowsoftware markets. These markets are growing strongly and the Company believes it has significantopportunities for growth. For example, data published by Global IndustryAnalysts, Inc.(1) indicates that the world electronic thermal managementsoftware market will continue to grow by 10% per year over the next five years.The Company's electronics cooling business is well positioned to benefit fromthis growth, particularly in Asia and the Far-East, which has seen strong growthin recent years. Similarly, the computer-aided engineering industry is expected to grow at acompound annual growth rate of 12% through 2009(2). The Board believesFlomerics' products can outperform this average market growth rate due to thecompetitive advantages offered by its products. Strong growth has already beenseen for the Engineering Fluid Dynamics (EFD) product range in 2007 and into2008. The investment in sales and marketing in 2007, aimed at accelerating revenuegrowth particularly from the EFD product range (acquired as part of theacquisition of Nika GmbH in 2006) is beginning to show positive results. Thisreinforces the Board's confidence that 2008 revenues will show considerableimprovement over 2007. Flomerics has cash balances of approximately £5.0m compared to £2.7m as at 31December 2007, and the Company is well funded to undertake the investment neededto deliver its strategy. Following on from the acquisitions of MicReD in 2005and Nika GmbH in 2006, additional growth through targeted acquisition remains animportant focus for the Company. The board continues to review potentialcandidates against its strategic and financial targets. The Company expects to announce its preliminary results for 2007 on 29 April. Enquiries: Flomerics Group plc +44 20 8487 3000Gary Carter, Chief ExecutiveKeith Butcher, Finance Director Conduit PR +44 20 7429 6604Christian Taylor-Wilkinson, Charlie Geller +44 7970 067320 Oriel Securities Limited +44 20 7710 7600Nominated AdviserDavid ArchAndrew Edwards For further details regarding the source information used in this announcementplease contact Charlie Geller, Conduit PR, on 0207 429 6604 -------------------------- (1) Source: PRWeb(2) Source: Daratech Inc This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th May 20247:00 amRNSExercise of Options and Total Voting Rights
17th May 20242:54 pmRNSNotice of AGM
9th May 20247:00 amRNSAnnual Financial Report
1st May 20247:00 amRNSHolding(s) in Company
18th Apr 20244:10 pmRNSDirector/PDMR Shareholding
27th Mar 20242:28 pmRNSClarification note regarding Dividend - REPLACE
26th Mar 20247:16 amRNS2023 Annual Unaudited Results
25th Mar 202411:44 amRNSNotice of Results
1st Feb 202410:38 amRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSTrading update
19th Dec 20237:00 amRNSHolding(s) in Company
25th Oct 202311:42 amRNSHolding(s) in Company
31st Aug 20234:25 pmRNSBoard Update
31st Aug 20237:00 amRNSPDMRs - Director Dealings
30th Aug 20237:00 amRNS2023 Half-year report
31st Jul 20237:00 amRNSTrading update & Notice of Half-year results
13th Jun 20231:42 pmRNSResult of AGM
5th Jun 20237:00 amRNSAwards under Long-Term Incentive Plan
5th Jun 20237:00 amRNSBoard update
19th May 20237:00 amRNSAvailability of Documents & Notice of 2023 AGM
15th May 20237:00 amRNSDirector Dealing
26th Apr 20237:01 amRNSAudited Annual Financial Report FY2022
12th Apr 20237:00 amRNSDirectorate Change
12th Apr 20237:00 amRNSUnaudited Preliminary Results-year ended 31.12.22
24th Mar 20237:00 amRNSNotice of Results - revised date
9th Mar 20238:00 amRNSAnnual Results and Presentation via IMC Platform
26th Jan 20237:00 amRNSTrading Update and Notice of Results
11th Jan 20237:00 amRNSBoard changes: NED Appointment & NED Retirement
21st Dec 20224:39 pmRNSHolding(s) in Company
31st Aug 20227:00 amRNSHalf-year Report - six months ended 30 June 2022
8th Aug 20226:27 pmRNSHolding(s) in Company
4th Aug 20227:30 amRNS2022 Half-Year Results - Investor Presentation
1st Aug 20227:00 amRNSGroup Trading Update & Notice of HY1 2022 results
21st Jul 20221:03 pmRNSHolding(s) in Company
1st Jun 20222:23 pmRNSResult of AGM and Total Voting Rights
18th May 20227:00 amRNSDirector/PDMR Shareholding
5th May 20222:20 pmRNS2021 Annual Report & Notice of 2022 AGM
3rd May 20227:00 amRNSGrant of Options under Long-Term Incentive Plan
30th Mar 20221:21 pmRNSDirector/PDMR Shareholding
29th Mar 20227:00 amRNSFY2021 Results & publication of the Annual Report
25th Mar 20225:36 pmRNSHolding(s) in Company
7th Mar 20229:00 amRNSNotice of Results and Investor Presentation
21st Feb 20225:49 pmRNSHolding(s) in Company
26th Jan 20227:01 amRNSTrading Statement
26th Jan 20227:00 amRNSAppointment of Nominated Adviser and Sole Broker
20th Jan 20224:41 pmRNSSecond Price Monitoring Extn
20th Jan 20224:36 pmRNSPrice Monitoring Extension
20th Dec 202112:58 pmRNSHolding(s) in Company
10th Dec 20214:41 pmRNSSecond Price Monitoring Extn
10th Dec 20214:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.